Clinical Trial Results:
An 8-week, Placebo-Controlled, Double-Blind, Randomized, Fixed-Dose Efficacy and Safety Trial of Asenapine in Adolescent Subjects with Schizophrenia
Summary
|
|
EudraCT number |
2009-017971-10 |
Trial protocol |
RO Outside EU/EEA |
Global end of trial date |
01 Apr 2013
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 May 2016
|
First version publication date |
23 Jul 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
P05896
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01190254 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
Merck Protocol number: MK-8274-020 | ||
Sponsors
|
|||
Sponsor organisation name |
Merck Sharp & Dohme Corp.
|
||
Sponsor organisation address |
2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
|
||
Public contact |
Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
|
||
Scientific contact |
Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Apr 2013
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Apr 2013
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with schizophrenia. Participants who qualify for the study will be randomly assigned to receive a fixed dose of asenapine (either 2.5 mg or 5 mg twice daily [BID]) or placebo for 8 weeks. Throughout the study, observations will be made on each participant at various times to assess the efficacy and safety of the study treatment. The primary objective of the trial is to demonstrate significant superiority of at least one asenapine dose to placebo, as measured by the change from baseline of the Positive and Negative Syndrome Scale (PANSS) total score at Day 56.
|
||
Protection of trial subjects |
This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research. The following additional measure defined for this individual study was in place for the protection of trial subjects: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
28 Sep 2010
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety, Efficacy | ||
Long term follow-up duration |
6 Months | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Colombia: 8
|
||
Country: Number of subjects enrolled |
Croatia: 6
|
||
Country: Number of subjects enrolled |
Romania: 6
|
||
Country: Number of subjects enrolled |
Bosnia and Herzegovina: 2
|
||
Country: Number of subjects enrolled |
India: 100
|
||
Country: Number of subjects enrolled |
Korea, Republic of: 3
|
||
Country: Number of subjects enrolled |
Mexico: 1
|
||
Country: Number of subjects enrolled |
Philippines: 1
|
||
Country: Number of subjects enrolled |
Russian Federation: 101
|
||
Country: Number of subjects enrolled |
Serbia: 9
|
||
Country: Number of subjects enrolled |
Ukraine: 17
|
||
Country: Number of subjects enrolled |
United States: 49
|
||
Country: Number of subjects enrolled |
South Africa: 3
|
||
Worldwide total number of subjects |
306
|
||
EEA total number of subjects |
12
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
1
|
||
Adolescents (12-17 years) |
304
|
||
Adults (18-64 years) |
1
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
- | ||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||
Screening details |
A total of 306 subjects were randomized to treatment with placebo (N=102), asenapine 2.5 mg BID (N=98) or asenapine 5.0 mg BID (N=106). | ||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer, Assessor | ||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants receive placebo asenapine tablets sublingually BID for 8 weeks | ||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
placebo
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Sublingual tablet
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Sublingual use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Asenapine-matched placebo tablets for sublingual administration
|
||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Asenapine 2.5 mg BID | ||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks | ||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
asenapine 2.5 mg
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||
Other name |
Saphris®, SCH 900274, Org 5222
|
||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Sublingual tablet
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Sublingual use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Asenapine 2.5 mg tablets for sublingual administration
|
||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Asenapine 5.0 mg BID | ||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period | ||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
asenapine 2.5 mg
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||
Other name |
Saphris®, SCH 900274, Org 5222
|
||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Sublingual tablet
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Sublingual use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Asenapine 2.5 mg tablets for sublingual administration
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
asenapine 5.0 mg
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||
Other name |
Saphris®, SCH 900274, Org 5222
|
||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Sublingual tablet
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Sublingual use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Asenapine 5.0 mg tablets for sublingual administration
|
||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants receive placebo asenapine tablets sublingually BID for 8 weeks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Asenapine 2.5 mg BID
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Asenapine 5.0 mg BID
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
Participants receive placebo asenapine tablets sublingually BID for 8 weeks | ||
Reporting group title |
Asenapine 2.5 mg BID
|
||
Reporting group description |
Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks | ||
Reporting group title |
Asenapine 5.0 mg BID
|
||
Reporting group description |
Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period |
|
|||||||||||||||||
End point title |
Change From Baseline in PANSS Total Score at Day 56 | ||||||||||||||||
End point description |
The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score for each participant was sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. The reported measure is the change from baseline at Day 56; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS); also, to be included an on-treatment Day 56 value of PANSS Total Score must be available for a participant.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± standard deviation (SD) change from baseline is 77 for placebo and 72 for asenapine 2.5 mg (total – 149). Mixed model for repeated measures (MMRM) analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
149
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.07 [1] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in Least Squares (LS) Means | ||||||||||||||||
Point estimate |
-4.8
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-9.9 | ||||||||||||||||
upper limit |
0.4 | ||||||||||||||||
Notes [1] - p-value is adjusted by Hochberg's method for testing two asenapine groups versus the placebo group. |
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 79 for asenapine 5.0 mg (total – 156). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.064 [2] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-5.6
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-10.7 | ||||||||||||||||
upper limit |
-0.5 | ||||||||||||||||
Notes [2] - p-value is adjusted by Hochberg's method for testing two asenapine groups versus the placebo group. |
|||||||||||||||||
Statistical analysis title |
Analysis of Dose-response: Linear Pattern | ||||||||||||||||
Statistical analysis description |
Investigation of dose-response relationship of change from baseline to Day 56 in PANSS Total Score was a Secondary study endpoint. Number of participants for calculation of reported mean ± SD changes from baseline is 228 (total for 3 groups). Multiple contrast testing using MMRM model (based on FAS population, total N = 300) was used to evaluate 3 pre-defined dose-response patterns (Linear, Convex, Concave).
|
||||||||||||||||
Comparison groups |
Placebo v Asenapine 2.5 mg BID v Asenapine 5.0 mg BID
|
||||||||||||||||
Number of subjects included in analysis |
228
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.064 [3] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Notes [3] - p-value (adjusted to control Type I error in multiple testing) for Linear dose-response pattern (Placebo<2.5 mg<5.0 mg) |
|||||||||||||||||
Statistical analysis title |
Analysis of Dose-response: Convex Pattern | ||||||||||||||||
Statistical analysis description |
Investigation of dose-response relationship of change from baseline to Day 56 in PANSS Total Score was a Secondary study endpoint. Number of participants for calculation of reported mean ± SD changes from baseline is 228 (total for 3 groups). Multiple contrast testing using MMRM model (based on FAS population, total N = 300) was used to evaluate 3 pre-defined dose-response patterns (Linear, Convex, Concave).
|
||||||||||||||||
Comparison groups |
Placebo v Asenapine 2.5 mg BID v Asenapine 5.0 mg BID
|
||||||||||||||||
Number of subjects included in analysis |
228
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.046 [4] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Notes [4] - p-value (adjusted to control Type I error in multiple testing) for Convex dose-response pattern (Placebo<2.5 mg=5.0 mg) |
|||||||||||||||||
Statistical analysis title |
Analysis of Dose-response: Concave Pattern | ||||||||||||||||
Statistical analysis description |
Investigation of dose-response relationship of change from baseline to Day 56 in PANSS Total Score was a Secondary study endpoint. Number of participants for calculation of reported mean ± SD changes from baseline is 228 (total for 3 groups). Multiple contrast testing using MMRM model (based on FAS population, total N = 300) was used to evaluate 3 pre-defined dose-response patterns (Linear, Convex, Concave).
|
||||||||||||||||
Comparison groups |
Placebo v Asenapine 2.5 mg BID v Asenapine 5.0 mg BID
|
||||||||||||||||
Number of subjects included in analysis |
228
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.273 [5] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Notes [5] - p-value (adjusted to control Type I error in multiple testing) for Concave dose-response pattern (Placebo=2.5 mg<5.0 mg) |
|
|||||||||||||||||
End point title |
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Day 56 | ||||||||||||||||
End point description |
Change from baseline in CGI-S score at Day 56 is the Key Secondary Outcome Measure. CGI-S is a 7-point scale for assessing the global severity of the participant’s illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from baseline at Day 56; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS); also, to be included a baseline and an on-treatment Day 56 value of the CGI-S score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 76 for placebo and 72 for asenapine 2.5 mg (total – 148). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
148
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.218 [6] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-0.2
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.5 | ||||||||||||||||
upper limit |
0.1 | ||||||||||||||||
Notes [6] - Confirmative testing for key secondary endpoint was to be performed only if both asenapine doses were superior to placebo in change from baseline in PANSS total score at Day 56. If this did not occur, multiplicity unadjusted p-values are provided. |
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 76 for placebo and 79 for asenapine 5.0 mg (total – 155). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.024 [7] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-0.3
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.6 | ||||||||||||||||
upper limit |
0 | ||||||||||||||||
Notes [7] - Confirmative testing for key secondary endpoint was to be performed only if both asenapine doses were superior to placebo in change from baseline in PANSS total score at Day 56. If this did not occur, multiplicity unadjusted p-values are provided. |
|
|||||||||||||||||
End point title |
Change From Baseline in PANSS Positive Subscale Score at Day 56 | ||||||||||||||||
End point description |
This measure reports results for the 7 items of the positive subscale of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Positive symptoms refer to an excess or distortion of normal mental status (e.g., delusions). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS positive subscale score for each participant was sum of the rating assigned to each of the 7 subscale items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms. Measure reports change from baseline; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS); also, to be included baseline and an on-treatment Day 56 value of PANSS positive subscale score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 72 for asenapine 2.5 mg (total – 149). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
149
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.067 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-1.6
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-3.3 | ||||||||||||||||
upper limit |
0.1 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 79 for asenapine 5.0 mg (total – 156). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.012 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-2.1
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-3.8 | ||||||||||||||||
upper limit |
-0.5 |
|
|||||||||||||||||
End point title |
Change From Baseline in PANSS Negative Subscale Score at Day 56 | ||||||||||||||||
End point description |
This measure reports results for the 7 items of the negative subscale of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Negative symptoms represent a diminution or loss of normal functions (e.g., emotional withdrawal). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS negative subscale score for each participant was sum of the rating assigned to each of the 7 subscale items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms. Measure reports change from baseline; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS); also, to be included baseline and an on-treatment Day 56 value of PANSS negative subscale score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 72 for asenapine 2.5 mg (total – 149). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
149
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.097 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-1.2
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-2.6 | ||||||||||||||||
upper limit |
0.2 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 79 for asenapine 5.0 mg (total – 156). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.099 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-1.2
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-2.6 | ||||||||||||||||
upper limit |
0.2 |
|
|||||||||||||||||
End point title |
Change From Baseline in PANSS Positive and Negative Subscale Scores Combined at Day 56 | ||||||||||||||||
End point description |
This measure reports results for combined positive (7 items) and negative (7 items) subscales of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. For each of the total 14 items in the combined positive and negative subscales, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS positive and negative subscale scores combined for each participant was sum of rating assigned to the 14 subscale items, and ranged from 14 to 98 with a higher score indicating greater severity of symptoms. Measure reports change from baseline; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline on-treatment PANSS Total Score (efficacy FAS); also, to be included a baseline and an on-treatment Day 56 value of PANSS positive/negative subscale scores combined must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 72 for asenapine 2.5 mg (total – 149). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
149
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.062 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-2.7
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-5.6 | ||||||||||||||||
upper limit |
0.1 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 79 for asenapine 5.0 mg (total – 156). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.025 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-3.2
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-6 | ||||||||||||||||
upper limit |
-0.4 |
|
|||||||||||||||||
End point title |
Change From Baseline in PANSS General Psychopathology Subscale Score at Day 56 | ||||||||||||||||
End point description |
This measure reports results for the 16 items of the general psychopathology subscale of the PANSS, which is a 30-item clinician-rated instrument used to assess the symptoms of schizophrenia. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS general psychopathology subscale score for each participant was calculated as the sum of the rating assigned to each of the 16 subscale items, and ranged from 16 to 112 with a higher score indicating greater severity of symptoms. The reported measure is the change from baseline at Day 56; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS); also, to be included a baseline and an on-treatment Day 56 value of the PANSS general psychopathology subscale score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 72 for asenapine 2.5 mg (total – 149). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
149
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.098 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-2.1
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-4.6 | ||||||||||||||||
upper limit |
0.4 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 79 for asenapine 5.0 mg (total – 156). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.071 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-2.3
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-4.8 | ||||||||||||||||
upper limit |
0.2 |
|
|||||||||||||||||
End point title |
Change From Baseline in PANSS Marder Positive Symptoms Factor Score at Day 56 | ||||||||||||||||
End point description |
This measure reports results for the 8 items of the Marder positive symptoms factor of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Marder factors are a modified grouping of the 30 PANSS items. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS Marder positive symptoms factor score for each participant was sum of rating assigned to each of the 8 applicable Marder factor items, and ranged from 8 to 56 with a higher score indicating greater severity of symptoms. Measure reports change from baseline; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (efficacy FAS); also, to be included baseline and an on-treatment Day 56 value of the PANSS Marder positive symptoms factor score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 72 for asenapine 2.5 mg (total – 149). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
149
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.106 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-1.4
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-3.1 | ||||||||||||||||
upper limit |
0.3 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 79 for asenapine 5.0 mg (total – 156). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.026 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-1.9
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-3.6 | ||||||||||||||||
upper limit |
-0.2 |
|
|||||||||||||||||
End point title |
Change From Baseline in PANSS Marder Negative Symptoms Factor Score at Day 56 | ||||||||||||||||
End point description |
This measure reports results for the 7 items of the Marder negative symptoms factor of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Marder factors are a modified grouping of the 30 PANSS items. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS Marder negative symptoms factor score for each participant was sum of the rating assigned to each of the 7 applicable Marder factor items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms. Measure reports change from baseline; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (efficacy FAS); also, to be included baseline and an on-treatment Day 56 value of the PANSS Marder negative symptoms factor score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 72 for asenapine 2.5 mg (total – 149). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
149
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.083 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-1.2
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-2.6 | ||||||||||||||||
upper limit |
0.2 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 79 for asenapine 5.0 mg (total – 156). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.067 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-1.3
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-2.7 | ||||||||||||||||
upper limit |
0.1 |
|
|||||||||||||||||
End point title |
Change From Baseline in PANSS Marder Disorganized Thoughts Factor Score at Day 56 | ||||||||||||||||
End point description |
This measure reports results for the 7 items of the Marder disorganized thoughts factor of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Marder factors are a modified grouping of the 30 PANSS items. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS Marder disorganized thoughts factor score for each participant was sum of rating assigned to each of the 7 applicable Marder factor items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms. Measure is change from baseline; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (efficacy FAS); also, to be included baseline and an on-treatment Day 56 value of PANSS Marder disorganized thoughts factor score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 72 for asenapine 2.5 mg (total – 149). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
149
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.131 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-0.9
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-2.1 | ||||||||||||||||
upper limit |
0.3 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 79 for asenapine 5.0 mg (total – 156). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.135 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-0.9
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-2.1 | ||||||||||||||||
upper limit |
0.3 |
|
|||||||||||||||||
End point title |
Change From Baseline in PANSS Marder Hostility/Excitement Factor Score at Day 56 | ||||||||||||||||
End point description |
This measure reports results for the 4 items of the Marder hostility/excitement factor of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Marder factors are a modified grouping of the 30 PANSS items. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS Marder hostility/excitement factor score for each participant was sum of rating assigned to each of the 4 applicable Marder factor items, and ranged from 4 to 28 with a higher score indicating greater severity of symptoms. Measure is change from baseline; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (efficacy FAS); also, to be included baseline and an on-treatment Day 56 value of PANSS Marder hostility/excitement factor score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 72 for asenapine 2.5 mg (total – 149). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
149
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.071 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-1
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-2 | ||||||||||||||||
upper limit |
0.1 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 79 for asenapine 5.0 mg (total – 156). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.12 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-0.8
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-1.9 | ||||||||||||||||
upper limit |
0.2 |
|
|||||||||||||||||
End point title |
Change From Baseline in PANSS Marder Anxiety/Depression Factor Score at Day 56 | ||||||||||||||||
End point description |
This measure reports results for the 4 items of the Marder anxiety/depression factor of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Marder factors are a modified grouping of the 30 PANSS items. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS Marder anxiety/depression factor score for each participant was sum of rating assigned to each of the 4 applicable Marder factor items, and ranged from 4 to 28 with a higher score indicating greater severity of symptoms. Measure is change from baseline; improvement in symptoms is represented by negative values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (efficacy FAS); also, to be included baseline and an on-treatment Day 56 value of the PANSS Marder anxiety/depression factor score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 72 for asenapine 2.5 mg (total – 149). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
149
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.263 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-0.4
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-1.2 | ||||||||||||||||
upper limit |
0.3 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 77 for placebo and 79 for asenapine 5.0 mg (total – 156). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.146 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-0.5
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-1.3 | ||||||||||||||||
upper limit |
0.2 |
|
|||||||||||||
End point title |
Total PANSS 30% Responders | ||||||||||||
End point description |
A Total PANSS 30% responder was defined as a participant who had a reduction from baseline of at least 30% in the PANSS Total score at the last available assessment of the study for that participant (i.e., endpoint). The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The Total score is the sum of the ratings for the individual items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline up to Day 56
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||
Statistical analysis description |
Model included terms of (pooled) site, treatment, and baseline PANSS Total Score. Odds ratio (OR) was adjusted for baseline and (pooled) site. An OR of >1 is considered to mean that asenapine has a higher probability of achieving Total PANSS 30% response.
|
||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||
Number of subjects included in analysis |
196
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.028 [8] | ||||||||||||
Method |
Regression, Logistic | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
2
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1.1 | ||||||||||||
upper limit |
3.6 | ||||||||||||
Notes [8] - p-value and 95% Confidence Interval are based on Wald statistic |
|||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||
Statistical analysis description |
Model included terms of (pooled) site, treatment, and baseline PANSS Total Score. OR was adjusted for baseline and (pooled) site. An OR of >1 is considered to mean that asenapine has a higher probability of achieving Total PANSS 30% response.
|
||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||
Number of subjects included in analysis |
204
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.048 [9] | ||||||||||||
Method |
Regression, Logistic | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
1.8
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1 | ||||||||||||
upper limit |
3.3 | ||||||||||||
Notes [9] - p-value and 95% Confidence Interval are based on Wald statistic |
|
|||||||||||||||||
End point title |
Kaplan-Meier Estimate of Cumulative Percentage of Participants With Total PANSS 30% Response at End of Study | ||||||||||||||||
End point description |
A total PANSS 30% response was defined as a reduction from baseline of at least 30% in the PANSS Total score. The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The Total score is the sum of the ratings for the individual items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. The Kaplan-Meier estimate reports the cumulative percentage of participants with total PANSS 30% response from first drug intake up to approximately Day 59. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline up to approximately Day 59
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Test of Difference in Time to Event Curves | ||||||||||||||||
Comparison groups |
Placebo v Asenapine 2.5 mg BID v Asenapine 5.0 mg BID
|
||||||||||||||||
Number of subjects included in analysis |
300
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.576 [10] | ||||||||||||||||
Method |
Logrank | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Notes [10] - p-value is for Log Rank test of difference in time to event (PANSS 30% response) curves between the three treatment groups |
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Model included factors for (pooled) site, treatment and baseline PANSS Total Score. A Hazard ratio (HR) of >1 is considered to mean that asenapine has a higher likelihood of being a Total PANSS 30% Responder than placebo.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
196
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.171 | ||||||||||||||||
Method |
Regression, Cox | ||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||
Point estimate |
1.3
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
0.9 | ||||||||||||||||
upper limit |
2 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Model included factors for (pooled) site, treatment and baseline PANSS Total Score. A Hazard ratio (HR) of >1 is considered to mean that asenapine has a higher likelihood of being a Total PANSS 30% Responder than placebo.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
204
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.368 | ||||||||||||||||
Method |
Regression, Cox | ||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||
Point estimate |
1.2
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
0.8 | ||||||||||||||||
upper limit |
1.8 |
|
|||||||||||||||||
End point title |
Clinical Global Impression of Improvement (CGI-I) Score at Day 56 | ||||||||||||||||
End point description |
CGI-I is a 7-point scale for assessing the global improvement of the participant’s illness relative to baseline, with ratings from 1=very much improved to 7=very much worse. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS); also, to be included an on-treatment Day 56 value of the CGI-I score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 76 for placebo and 72 for asenapine 2.5 mg (total – 148). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit and the interaction of visit by treatment.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
148
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.094 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-0.3
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.6 | ||||||||||||||||
upper limit |
0 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 76 for placebo and 79 for asenapine 5.0 mg (total – 155). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit and the interaction of visit by treatment.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.003 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
-0.5
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.8 | ||||||||||||||||
upper limit |
-0.2 |
|
|||||||||||||
End point title |
CGI-I Responders | ||||||||||||
End point description |
A CGI-I responder was defined as a participant who had a CGI-I score of 1 (very much improved) or 2 (much improved) at the last available assessment of the study for that participant (i.e., endpoint). CGI-I is a 7-point scale for assessing the global improvement of the participant’s illness relative to baseline, with ratings from 1=very much improved to 7=very much worse. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline up to Day 56
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||
Statistical analysis description |
Model included terms of region (Asia-Pacific, North America, Eastern Europe [Africa/Latin America sites assigned to this region]) and treatment. OR was adjusted for region. An OR of >1 is considered to mean that asenapine has a higher probability of achieving CGI-I response.
|
||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||
Number of subjects included in analysis |
196
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.177 [11] | ||||||||||||
Method |
Regression, Logistic | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
1.5
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.8 | ||||||||||||
upper limit |
2.8 | ||||||||||||
Notes [11] - p-value and 95% Confidence Interval are based on Wald statistic |
|||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||
Statistical analysis description |
Model included terms of region (Asia-Pacific, North America, Eastern Europe [Africa/Latin America sites assigned to this region]) and treatment. OR was adjusted for region. An OR of >1 is considered to mean that asenapine has a higher probability of achieving CGI-I response.
|
||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||
Number of subjects included in analysis |
204
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.114 [12] | ||||||||||||
Method |
Regression, Logistic | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
1.6
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.9 | ||||||||||||
upper limit |
2.9 | ||||||||||||
Notes [12] - p-value and 95% Confidence Interval are based on Wald statistic |
|
|||||||||||||||||
End point title |
Kaplan-Meier Estimate of Cumulative Percentage of Participants With CGI-I Response at End of Study | ||||||||||||||||
End point description |
CGI-I response was defined as the occurrence of a CGI-I score of 1 (very much improved) or 2 (much improved). CGI-I is a 7-point scale for assessing the global improvement of the participant’s illness relative to baseline, with ratings from 1=very much improved to 7=very much worse. The Kaplan-Meier estimate reports the cumulative percentage of participants with CGI-I response from first drug intake up to approximately Day 58. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline up to approximately Day 58
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Test of Difference in Time to Event Curves | ||||||||||||||||
Comparison groups |
Placebo v Asenapine 2.5 mg BID v Asenapine 5.0 mg BID
|
||||||||||||||||
Number of subjects included in analysis |
300
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.057 [13] | ||||||||||||||||
Method |
Logrank | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Notes [13] - p-value is for Log Rank test of difference in time to event (CGI-I response) curves between the three treatment groups |
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Model included factors for (pooled) site and treatment. An HR of >1 is considered to mean that asenapine has a higher likelihood of being a CGI-I Responder than placebo.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
196
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.135 | ||||||||||||||||
Method |
Regression, Cox | ||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||
Point estimate |
1.4
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
0.9 | ||||||||||||||||
upper limit |
2.3 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Model included factors for (pooled) site and treatment. An HR of >1 is considered to mean that asenapine has a higher likelihood of being a CGI-I Responder than placebo.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
204
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.01 | ||||||||||||||||
Method |
Regression, Cox | ||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||
Point estimate |
1.8
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
1.2 | ||||||||||||||||
upper limit |
2.9 |
|
|||||||||||||||||
End point title |
Change From Baseline in Children’s Global Assessment Scale (CGAS) Score at Day 56 | ||||||||||||||||
End point description |
CGAS is a 100-point scale measuring psychological, social, and school functioning in children aged 6-17. Minimum scores ranged from 1-10, representing the need for constant supervision (worse result) to maximum scores of 91-100, representing superior functioning (better result). The reported measure is the change from baseline at Day 56; improvement in functioning is represented by positive values. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS); also, to be included a baseline and an on-treatment Day 56 value of the CGAS score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 76 for placebo and 72 for asenapine 2.5 mg (total – 148). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
148
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.417 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
1.4
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-2 | ||||||||||||||||
upper limit |
4.8 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Number of participants for calculation of reported mean ± SD change from baseline is 76 for placebo and 79 for asenapine 5.0 mg (total – 155). MMRM analysis uses FAS population (Number of participants: placebo – 100, asenapine 2.5 mg – 96, asenapine 5.0 mg – 104). Model includes terms of (pooled) site, treatment, visit, baseline, and the interaction of visit by treatment and baseline by visit.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.017 | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
4.2
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
0.8 | ||||||||||||||||
upper limit |
7.6 |
|
|||||||||||||||||
End point title |
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score at Day 56 | ||||||||||||||||
End point description |
PQ-LES-Q is a questionnaire to assess quality of life enjoyment and satisfaction in children and adolescents. Participant rates 15 items on a scale of 1=very poor to 5=very good. Items 1-14 assess specific areas; Item 15 is a global assessment. PQ-LES-Q total score for each participant was sum of rating assigned to first 14 items, and ranged from 14 to 70 with a higher score indicating better quality of life. Measure reports change from baseline; improvement in quality of life is represented by positive values. Last-observation-carried-forward (LOCF) approach was used; if no Day 56 value was available, the last available assessment prior to Day 56 assessment was used. Population for analysis was randomized participants who received ≥1 dose of study drug and had both baseline and ≥1 post-baseline on-treatment PANSS Total Score (efficacy FAS); also, to be included baseline and ≥1 post-baseline on-treatment value of PQ-LES-Q total score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
Analysis of covariance (ANCOVA) model includes terms of (pooled) site, treatment and baseline.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.6 | ||||||||||||||||
Method |
ANCOVA | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
0.6
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-1.6 | ||||||||||||||||
upper limit |
2.8 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
ANCOVA model includes terms of (pooled) site, treatment and baseline.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
167
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.064 | ||||||||||||||||
Method |
ANCOVA | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
2.1
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.1 | ||||||||||||||||
upper limit |
4.3 |
|
|||||||||||||||||
End point title |
Change From Baseline in PQ-LES-Q Overall Score (i.e., Item 15) at Day 56 | ||||||||||||||||
End point description |
PQ-LES-Q is a questionnaire to assess quality of life enjoyment and satisfaction in children and adolescents. Participant rates 15 items on a scale of 1=very poor to 5=very good. Items 1-14 assess specific areas; Item 15 is a global assessment. The Item 15 result is defined to be the PQ-LES-Q overall score, and ranged from 1 to 5 with a higher score indicating better quality of life. Measure reports change from baseline; improvement in quality of life is represented by positive values. LOCF approach was used; if no Day 56 value was available, the last available assessment prior to Day 56 assessment was used. Population for analysis was randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline on-treatment PANSS Total Score (this group is termed the efficacy FAS); also, to be included a baseline and ≥1 post-baseline on-treatment value of the PQ-LES-Q overall score must be available for a participant.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and Day 56
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
ANCOVA model includes terms of (pooled) site, treatment and baseline.
|
||||||||||||||||
Comparison groups |
Asenapine 2.5 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.407 | ||||||||||||||||
Method |
ANCOVA | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
0.1
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.13 | ||||||||||||||||
upper limit |
0.33 | ||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||
Statistical analysis description |
ANCOVA model includes terms of (pooled) site, treatment and baseline.
|
||||||||||||||||
Comparison groups |
Asenapine 5.0 mg BID v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
167
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.111 | ||||||||||||||||
Method |
ANCOVA | ||||||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||||||
Point estimate |
0.19
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.04 | ||||||||||||||||
upper limit |
0.42 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to 30 days after the last dose of study drug
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
15.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants receive placebo asenapine tablets sublingually BID for 8 weeks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Asenapine 2.5 mg BID
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Asenapine 5.0 mg BID
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
23 Sep 2011 |
Amendment 01: Primary reason for amendment was to incorporate revisions to text presenting tapering periods for discontinuation of prohibited medications prior to study and upper limit of age range for entry into extension trial (Protocol P05897). |
||
03 May 2012 |
Amendment 02: Primary reason for amendment was to incorporate revisions to requirements for final visit for subjects enrolling in extension trial (Protocol P05897), measures included in key secondary objectives, identification of staff qualified to administer an efficacy assessment, allowed concomitant medications/rescue therapy, list of closely monitored events, statistical analysis and procedures for liver enzyme monitoring. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |